Long-Term Weight Change after Initiating Second-Generation Antidepressants

Area of Science:

• Pharmacology
• Clinical Medicine
• Psychiatry

Background:

• Second-generation antidepressants are widely prescribed for depression.
• Long-term weight changes associated with antidepressant use require further investigation.
• Understanding medication-specific weight effects is crucial for patient management.

Purpose of the Study:

• To analyze the association between specific second-generation antidepressant medications and long-term weight change.
• To compare weight changes at two years across different antidepressant treatment initiations.
• To identify antidepressants with favorable or unfavorable weight profiles.

Main Methods:

• Retrospective cohort study design utilizing electronic health records.
• Inclusion of adult patients initiating a new antidepressant treatment episode between 2006 and 2009.
• Inverse probability weighted linear regression models to assess weight and BMI changes at two years, adjusting for confounders.

Main Results:

• Bupropion treatment was associated with an average weight loss of 7.1 lbs in non-smokers compared to fluoxetine.
• Bupropion treatment showed no significant weight change in smokers compared to fluoxetine.
• Sertraline treatment was associated with an average weight gain of 5.9 lbs compared to fluoxetine; other antidepressants showed no significant differences.

Conclusions:

• Antidepressant drug therapy significantly influences long-term weight changes over two years.
• Bupropion may be a preferred first-line option for overweight/obese patients due to its association with weight loss.
• Individualized treatment decisions considering weight effects are recommended.